Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (VERA)
CUSIP: 92337R101
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Class A Common Stock, par value $0.001 per share
- Shares outstanding
- 72,325,000
- Total 13F shares
- 63,893,006
- Share change
- +884,951
- Total reported value
- $1,505,324,602
- Put/Call ratio
- 24%
- Price per share
- $23.56
- Number of holders
- 171
- Value change
- +$17,298,219
- Number of buys
- 104
- Number of sells
- 87
Quarterly Holders Quick Answers
What is CUSIP 92337R101?
CUSIP 92337R101 identifies VERA - Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 92337R101:
Top shareholders of VERA - Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Avoro Capital Advisors LLC |
13F
13D/G
|
Company |
8.9%
from 13D/G
|
5,701,900
|
$136,959,638 | — | 31 Mar 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
6.6%
|
4,754,832
|
$114,212,000 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
5.5%
|
3,992,537
|
$95,900,750 | — | 31 Mar 2025 | |
| Kynam Capital Management, LP |
13D/G
13F
|
Company |
5.4%
|
3,426,887
|
$83,444,698 | $0 | 30 Jun 2025 | |
| Commodore Capital LP |
3/4/5
13F
|
10%+ Owner · Company |
3.5%
from 13F
|
4,400,000
|
$79,200,000 | — | 10 Jan 2024 | |
| FMR LLC |
13F
|
Company |
4.5%
|
3,232,319
|
$77,640,303 | — | 31 Mar 2025 | |
| James E. Flynn |
13D/G
|
Deerfield Mgmt, L.P. |
5.2%
|
3,348,117
|
$75,299,151 | $0 | 06 Jun 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4%
|
2,918,423
|
$70,100,521 | — | 31 Mar 2025 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
3.9%
|
2,793,987
|
$67,111,568 | — | 31 Mar 2025 | |
| Sofinnova Venture Partners X, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,467,156
|
$62,408,808 | — | 06 Feb 2023 | |
| Vestal Point Capital, LP |
13F
|
Company |
3.5%
|
2,500,000
|
$60,050,000 | — | 31 Mar 2025 | |
| Emster Kurt von |
3/4/5
|
Director |
—
mixed-class rows
|
2,987,984
mixed-class rows
|
$53,605,062 | — | 17 May 2021 | |
| Abingworth LLP |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
2,970,156
mixed-class rows
|
$53,284,158 | — | 13 May 2021 | |
| Carlyle Group Inc. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,960,231
|
$53,284,158 | — | 17 Aug 2022 | |
| Holocene Advisors, LP |
13F
|
Company |
3%
|
2,199,292
|
$52,826,994 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.9%
|
2,083,048
|
$50,034,813 | — | 31 Mar 2025 | |
| Eversept Partners, LP |
13F
|
Company |
2.6%
|
1,898,804
|
$45,609,272 | — | 31 Mar 2025 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
2.3%
|
1,675,367
|
$40,243,000 | — | 31 Mar 2025 | |
| Longitude Capital Partners IV, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,714,285
|
$30,857,130 | — | 06 Feb 2023 | |
| Longitude Prime Partners, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,714,285
|
$30,857,130 | — | 06 Feb 2023 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.7%
|
1,202,809
|
$28,898,751 | — | 31 Mar 2025 | |
| First Light Asset Management, LLC |
13F
|
Company |
1.6%
|
1,175,879
|
$28,244,614 | — | 31 Mar 2025 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
1.6%
|
1,150,000
|
$27,623,000 | — | 31 Mar 2025 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
1.5%
|
1,050,000
|
$25,221,000 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
1.4%
|
1,000,849
|
$24,040,393 | — | 31 Mar 2025 | |
| SAMLYN CAPITAL, LLC |
13F
|
Company |
1.4%
|
978,423
|
$23,501,719 | — | 31 Mar 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
1.2%
|
892,859
|
$21,446,473 | — | 31 Mar 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
1.2%
|
840,258
|
$20,182,997 | — | 31 Mar 2025 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
1.1%
|
788,150
|
$18,931,363 | — | 31 Mar 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
1%
|
747,216
|
$17,948,128 | — | 31 Mar 2025 | |
| THORNBURG INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.09%
|
66,572
|
$15,990,594 | — | 31 Mar 2025 | |
| VOYA INVESTMENT MANAGEMENT LLC |
13F
|
Company |
0.87%
|
627,357
|
$15,069,115 | — | 31 Mar 2025 | |
| First Turn Management, LLC |
13F
|
Company |
0.86%
|
623,612
|
$14,979,160 | — | 31 Mar 2025 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.72%
|
520,796
|
$12,509,520 | — | 31 Mar 2025 | |
| SCHRODER INVESTMENT MANAGEMENT GROUP |
13F
|
Company |
0.63%
|
458,841
|
$12,218,936 | — | 31 Mar 2025 | |
| JENNISON ASSOCIATES LLC |
13F
|
Company |
0.7%
|
507,838
|
$12,198,269 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.7%
|
505,918
|
$12,152,151 | — | 31 Mar 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.67%
|
481,065
|
$11,555,181 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.64%
|
459,667
|
$11,041,202 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.61%
|
440,689
|
$10,585,349 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.59%
|
424,940
|
$10,207,059 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.58%
|
418,259
|
$10,046,581 | — | 31 Mar 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
0.57%
|
415,719
|
$9,985,570 | — | 31 Mar 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.52%
|
377,450
|
$9,066,385 | — | 31 Mar 2025 | |
| S.c.a. Candriam |
13F
|
Individual |
0.5%
|
363,692
|
$8,735,882 | — | 31 Mar 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.49%
|
355,143
|
$8,530,535 | — | 31 Mar 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.48%
|
344,623
|
$8,277,844 | — | 31 Mar 2025 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
0.41%
|
300,000
|
$7,206,000 | — | 31 Mar 2025 | |
| Beth C. Seidenberg |
3/4/5
|
Director |
—
mixed-class rows
|
149,565
mixed-class rows
|
$6,715,972 | — | 14 May 2025 | |
| GW&K Investment Management, LLC |
13F
|
Company |
0.35%
|
252,240
|
$6,059,000 | — | 31 Mar 2025 |
Institutional Holders of Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (VERA) as of Q2 2025
As of 30 Jun 2025,
Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (VERA) was held by
171 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
63,893,006 shares.
The largest 10 holders included
Avoro Capital Advisors LLC, PRICE T ROWE ASSOCIATES INC /MD/, BlackRock, Inc., Kynam Capital Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Vestal Point Capital, LP, VANGUARD GROUP INC, FMR LLC, Sofinnova Investments, Inc., and Woodline Partners LP.
This page lists
171
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
176
Q2 2025 holders
171
Holder diff
-5
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.